Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KaloBios CEO retires following drug failures

This article was originally published in Scrip

Executive Summary

David W Pritchard, CEO of California's KaloBios, has retired from the company with immediate effect, just days after the company announced its latest clinical failure. The company was not immediately available to comment on whether the timing of Mr Pritchard's retirement was linked to the failure of KB001-A earlier this week (scripintelligence.com, 7 January 2015). KB001-A's failure followed that of KB003 in January 2014. CFO Herb C Cross has been appointed interim CEO pending a search for a permanent replacement for Mr Pritchard.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC027469

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel